First Approval for a New Immune Checkpoint Inhibitor
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adult patients with...